Department of Radiology, Washington University, St Louis, Missouri 63110, USA.
J Nucl Med. 2011 Dec;52(12):1956-63. doi: 10.2967/jnumed.111.089581. Epub 2011 Nov 2.
Sensitive, specific, and noninvasive detection of angiogenesis would be helpful in discovering new strategies for the treatment of cardiovascular diseases. Recently, we reported the (64)Cu-labeled C-type atrial natriuretic factor (CANF) fragment for detecting the upregulation of natriuretic peptide clearance receptor (NPR-C) with PET on atherosclerosis-like lesions in an animal model. However, it is unknown whether NPR-C is present and overexpressed during angiogenesis. The goal of this study was to develop a novel CANF-integrated nanoprobe to prove the presence of NPR-C and offer sensitive detection with PET during development of angiogenesis in mouse hind limb.
We prepared a multifunctional, core-shell nanoparticle consisting of DOTA chelators attached to a poly(methyl methacrylate) core and CANF-targeting moieties attached to poly(ethylene glycol) chain ends in the shell of the nanoparticle. Labeling of this nanoparticle with (64)Cu yielded a high-specific-activity nanoprobe for PET imaging NPR-C receptor in a mouse model of hind limb ischemia-induced angiogenesis. Histology and immunohistochemistry were performed to assess angiogenesis development and NPR-C localization.
(15)O-H(2)O imaging showed blood flow restoration in the previously ischemic hind limb, consistent with the development of angiogenesis. The targeted DOTA-CANF-comb nanoprobe showed optimized pharmacokinetics and biodistribution. PET imaging demonstrated significantly higher tracer accumulation for the targeted DOTA-CANF-comb nanoprobe than for either the CANF peptide tracer or the nontargeted control nanoprobe (P < 0.05, both). Immunohistochemistry confirmed NPR-C upregulation in the angiogenic lesion with colocalization in both endothelial and smooth muscle cells. PET and immunohistochemistry competitive receptor blocking verified the specificity of the targeted nanoprobe to NPR-C receptor.
As evidence of its translational potential, this customized DOTA-CANF-comb nanoprobe demonstrated superiority over the CANF peptide alone for imaging NPR-C receptor in angiogenesis.
本研究旨在开发一种新型的 CANF 整合纳米探针,以证实 NPR-C 的存在,并在小鼠后肢血管生成过程中提供 PET 的敏感检测。
我们制备了一种多功能核壳纳米粒子,该纳米粒子由附着在聚甲基丙烯酸甲酯核上的 DOTA 螯合剂和附着在纳米粒子壳的聚乙二醇链末端的 CANF 靶向部分组成。用 (64)Cu 对该纳米粒子进行标记,得到一种高比活度的纳米探针,用于 PET 成像在小鼠后肢缺血性血管生成模型中的 NPR-C 受体。进行组织学和免疫组织化学检查以评估血管生成的发展和 NPR-C 的定位。
(15)O-H(2)O 成像显示先前缺血后肢的血流恢复,与血管生成的发展一致。靶向 DOTA-CANF 组合纳米探针表现出优化的药代动力学和生物分布。PET 成像显示,与 CANF 肽示踪剂或非靶向对照纳米探针相比,靶向 DOTA-CANF 组合纳米探针的示踪剂积累明显更高(均 P < 0.05)。免疫组织化学证实,在血管生成病变中 NPR-C 上调,内皮细胞和平滑肌细胞中均有共定位。PET 和免疫组织化学竞争性受体阻断实验证实了靶向纳米探针对 NPR-C 受体的特异性。
作为其转化潜力的证据,这种定制的 DOTA-CANF 组合纳米探针在血管生成中成像 NPR-C 受体方面优于单独的 CANF 肽。